<!DOCTYPE html>
<html lang="en">
<head>
<title>Migraine</title>
<meta http-equiv="Content-Type" content="text/html;charset=utf-8">
<link rel="stylesheet" type="text/css" href="../../../public/css/offline.css" />
<script src="../../../public/javascripts/jquery-1.10.2.min.js"></script>
</head>
<body class="dsg-wb">

<table width="80%" class="offline">
<tr>
  <td colspan="3" class="header"><h1><a href="/">JPAC</a> <span>Joint United Kingdom (UK) Blood Transfusion and Tissue Transplantation Services Professional Advisory Committee</span></h1></td>
</tr>
<tr class="tabs">
  <td colspan="3">
              <ul>
                  <li id="64df60ce-a8e2-4c07-8729-68f41eb42fc3" class="whole-blood-and-components"><a href="../../../dsg/wb/guidelines.html"  class="active">Whole Blood and Components</a></li>
                  <li id="ddb09bf2-3dc0-4eb2-ba57-a5db69331dd1" class="geographical-disease-risk-index"><a href="../../../dsg/gdri/guidelines.html" >Geographical Disease Risk Index</a></li>
                </ul>
        </td>
</tr>
<tr>
  <td class="spacerow" colspan="3"></td>
</tr>
<tr>
  <td class="sidebar" width="25%">
    <div class="well">
          <ul class="openContentSectionWithSubs sidebarTopHeader"><li id="64df60ce-a8e2-4c07-8729-68f41eb42fc3" class="whole-blood-and-components sectionHead first last"><a href="../../../dsg/wb.html">Whole Blood and Components</a>
<ul class="">
<li id="42be2de8-89aa-4908-8bc8-702f9e636a81" class="a-z-search active first"><a href="../../../dsg/wb/guidelines.html">A-Z Search</a>
</li><li id="1f7e1f13-8b29-4772-ae9d-2b5cc3d59491" class="updates"><a href="../../../dsg/wb/latest-updates.html">Updates</a>
</li><li id="f83d68fb-19de-4588-9a36-a8bba0aa6494" class="drug-index"><a href="../../../dsg/wb/drug-index.html">Drug Index</a>

</li><li id="769da873-1c35-4600-8be8-d2df902570a0" class="preliminaries"><a href="../../../dsg/wb/preliminaries.html">Preliminaries</a>
<ul class="">
<li id="258895c3-f3dd-45c6-932c-3fe4795870c2" class="introduction first"><a href="../../../dsg/wb/preliminaries/introduction.html">Introduction</a>
</li><li id="ef298454-8327-4f6c-9f4a-835e437df103" class="document-and-change-control"><a href="../../../dsg/wb/preliminaries/document-and-change-control.html">Document and Change Control</a>
</li><li id="093e6463-a089-49dd-9199-c8f92559f486" class="general-principles"><a href="../../../dsg/wb/preliminaries/general-principles.html">General Principles</a>
</li><li id="96f75c3a-2c62-445b-847c-353098eaec1e" class="medication"><a href="../../../dsg/wb/preliminaries/medication.html">Medication</a>
</li><li id="ed51942d-a7fd-42f7-8269-d23b879f99ca" class="inspection-of-the-donor"><a href="../../../dsg/wb/preliminaries/inspection-of-the-donor.html">Inspection of the Donor</a>
</li><li id="99af8b5e-491b-4d67-b69a-812d81af4d7d" class="use-of-alphabetical-listing last"><a href="../../../dsg/wb/preliminaries/use-of-alphabetical-listing.html">Use of Alphabetical Listing</a>
</li></ul>
</li><li id="753eb36f-2636-414c-84ee-1004e197502d" class="appendices"><a href="../../../dsg/wb/appendicies.html">Appendices</a>
<ul class="">
<li id="e147bd96-a025-4ffa-b530-b9abefc27043" class="appendix-1---estimated-blood-volume-for-female-donors-after-nadler--by-height-and-weight first"><a href="../../../dsg/wb/appendicies/appendix-1.html">Appendix 1 - Estimated Blood Volume for Female donors (after Nadler)  by height and weight</a>
</li><li id="2f1eca54-e34f-4ece-90a4-7dfe0f210c8d" class="appendix-2---table-of-immunisations-"><a href="../../../dsg/wb/appendicies/appendix-2-table-of-immunizations.html">Appendix 2 - Table of Immunisations </a>
</li><li id="a27f8ce9-b4f6-4a9b-baf0-6f655955a9aa" class="appendix-3---maximum-permitted-ecv-for-component-donors"><a href="../../../dsg/wb/appendicies/appendix-3-maximum-permitted-extra-corporeal-volume-for-component-donors.html">Appendix 3 - Maximum permitted ECV for component donors</a>
</li><li id="90c869cb-7256-4604-8699-d8a86f78aa26" class="appendix-4---management-of-post-donation-illness last"><a href="../../../dsg/wb/appendicies/appendix-4-management-of-post-donation-illness.html">Appendix 4 - Management of post donation illness</a>
</li></ul>
</li><li id="b62a2d12-6d94-4106-92a8-1de426a4b863" class="source-files last"><a href="../../../dsg/wb/source-files.html">Source Files</a>
</li></ul>
</li></ul>
    </div>
  </td>
  <td width="5%"></td>
  <td width="70%" class="content">
    <h2>Migraine</h2>    

<table class="data-table"><tbody><tr class="data-row"><td class="data-label">Obligatory</td><td class="data-value"><p><b>Must not donate if:</b><br />
1. Migraine is severe.<br />
<br />
2. Migraine occurs more than once a week.<br />
<br />
3. On prophylactic treatment with sodium valproate (valproic acid), topiramate or a monoclonal antibody therapy.</p></td></tr><tr class="data-row"><td class="data-label">Discretionary</td><td class="data-value"><p>If the donor's migraine is not severe, and</p>


<ul>
	<li>it occurs less than once per week, and</li>
	<li>any treatment does not preclude donation,</li>
</ul>


<p>accept.</p></td></tr><tr class="data-row"><td class="data-label">See if Relevant</td><td class="data-value"><p><a href="../../../dsg/wb/guidelines/he002-headache.html">Headache</a><br />
<a href="../../../dsg/wb/guidelines/monoclonal-antibody-therapy-and-other-biological-modalities.html">Monoclonal antibody therapy and other Biological Modalities</a><br />
<a href="../../../dsg/wb/guidelines/no006-nonsteroidal-anti-inflammatory-drugs.html">Nonsteroidal anti-inflammatory drugs</a><br />
<a href="../../../dsg/wb/guidelines/valproate.html">Valproate and Topiramate</a></p></td></tr><tr class="data-row"><td class="data-label">Additional Information</td><td class="data-value"><p>Migraine is caused by a disturbance in the normal blood flow to parts of the brain. Severe forms can be associated with focal neurological signs and symptoms, such as hemiplegia, or result in the frequency and duration of symptoms limiting normal activities.<br />
<br />
By not accepting people with the more severe forms of migraine we hope to prevent precipitating an attack through the process of donating blood.<br />
<br />
Care should be taken to assess any medication the donor has taken, either as prophylaxis or as relief for a migraine. Such medication may include Valproate, Topiramate or new monoclonal antibody treatments that may mean the donor is not eligible to donate.<br />
<br />
Monoclonal antibody (MAb) therapy may be given to patients with frequent migraine where other preventative treatment has failed. MAb therapies are given by injection or by infusion. They include Eptinezumab (Vyepti<sup>&reg;</sup>), Erenumab (Aimovig<sup>&reg;</sup>), Fremanezumab (Ajovy<sup>&reg;</sup>), Galcanezumab (Emgality<sup>&reg;</sup>).<br />
<br />
Any donor who has had migraine associated with giving blood on more than one occasion should be advised not to continue as a donor.</p></td></tr><tr class="data-row"><td class="data-label">Reason for change</td><td class="data-value"><p>The entry has been revised including the addition of an obligatory deferral for prophylaxis with topiramate or monoclonal antibody therapy. The ‘See if Relevant’ section has been updated.</p></td></tr><tr class="data-row"><td class="data-label">Donor Information</td><td class="data-value"><p>If you wish to obtain more information regarding a personal medical issue, please contact your <a href="../../../dsg/wb/guidelines/nn099-national-help-lines.html">National Help Line</a>.<br />
<br />
Please do not contact this web site for personal medical queries, as we are not in a position to provide individual answers.</p></td></tr></tbody></table>
<div class="pull-right attachments"><div class="cms images">
  
</div></div>

  
<dl class="update-information"><dt class="data-label"><h4>Update Information</h4></dt><dd class="data-value"><p>This entry was last updated in:<br />
WB-DSG&nbsp;Edition 203&nbsp;Release 74</p></dd></dl>  </td>
</tr>
</table>
</body>
</html>